Incyte Corporation (INCY) : Riskx Investments has sold out all of its stake in Incyte Corporation during the most recent quarter, according to the disclosure filed by the company on Aug 1, 2016 with the SEC. The investment management company has sold out 9,755 shares of Incyte Corporation which is valued at $885,852.
Other Hedge Funds, Including , Financial Architects Inc boosted its stake in INCY in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 121 shares of Incyte Corporation which is valued at $10,735. Douglass Winthrop Advisors added INCY to its portfolio by purchasing 2,000 company shares during the most recent quarter which is valued at $165,120. Incyte Corporation makes up approx 0.01% of Douglass Winthrop Advisors’s portfolio.Next Financial Group Inc reduced its stake in INCY by selling 50 shares or 7.14% in the most recent quarter. The Hedge Fund company now holds 650 shares of INCY which is valued at $55,705. Incyte Corporation makes up approx 0.02% of Next Financial Group Inc’s portfolio.
Incyte Corporation closed down -0.69 points or -0.76% at $90.12 with 8,26,561 shares getting traded on Thursday. Post opening the session at $91.47, the shares hit an intraday low of $89.75 and an intraday high of $92.045 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Incyte Corporation reported $0.12 EPS for the quarter, based on the information available during the earnings call on May 9, 2016. Analyst had a consensus estimate of $0.12. The company had revenue of $263.50 million for the quarter, compared to analysts expectations of $264.41 million. The company’s revenue was up 65.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.
Many Wall Street Analysts have commented on Incyte Corporation. RBC Capital Mkts Initiated Incyte Corporation on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $105.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights f